<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03848533</url>
  </required_header>
  <id_info>
    <org_study_id>CT-MEL-LESM</org_study_id>
    <nct_id>NCT03848533</nct_id>
  </id_info>
  <brief_title>Effect of Melatonin and Metformin on Glycemic Control Genotoxicity and Cytotoxicity Markers in Patients With Prediabetes</brief_title>
  <official_title>Effect of the Administration of Melatonin and Metformin on Glycemic Control, Genotoxicity and Cytotoxicity Markers in Patients With Prediabetes: Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Guadalajara</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Guadalajara</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Melatonin is a hormone that regulates the circadian cycle in addition to having an
      antioxidant effect. Patients with prediabetes state, has a deregulation of glucose metabolism
      and an overproduction of reactive oxygen species caused by levels of hyperglycemia that
      generate DNA modification in pancreatic beta cells, which leads to apoptosis and a deficient
      production of insulin. The administration of metformin and melatonin could be a possibility
      to treat and reverse the prediabetic state decreasing the glycemic levels and reactive oxygen
      species production.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, double blind, placebo-controlled, pilot clinical trial will carried out in 42
      patients with a diagnosis of prediabetes, according to the American Diabetes Association
      criteria. The patients will be divide in three groups administrating metformin plus placebo,
      melatonin plus placebo or melatonin plus metformin. The intervention will be with 500 mg
      lengthed release tablets of metformin once a day in the morning, per 90 days, 5 mg lengthed
      release capsules of melatonin one a day in the night per 90 days and calcined magnesia as a
      placebo. Before and after the intervention, will be evaluate: fasting plasma glucose, blood
      glucose after an oral glucose tolerance test, A1c hemoglobin fraction, micronuclei frequency,
      nuclear anomalies frequency, insulin secretion and insulin sensitivity, weight, height, body
      mass index, triglycerides, total cholesterol, high-density lipoprotein, low-density
      lipoprotein, creatinine, uric acid, and sleep quality.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 22, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>It will be done using a sealed envelope, which will contain a letter A, B or C, and will be given to choose an envelope to the participants. The letter obtained will indicate the group to which the subject will belong during the intervention. The intervention designated for each of the groups will be unknown by the researcher and participants.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Fasting plasma glucose (FPG)</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>The FPG will be evaluate in a blood sample after a 8 - 12 hour fasting period. Will be use a fotometric quantification of glucose levels in plasma sample and will report in mg/dL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Glucose level after an Oral Glucose tolerance Test</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>Will estimate the glucose levels at 2 hours after administration of 75 grams of anhydrid dextrosa. The result will report in mg/dL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>A1c Hemoglobin Fraction (HbA1C)</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>HbA1c will be measured with High-performance liquid chromatography technique from a blood sample. The result will report in percentage (%).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Micronuclei frequency</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>The frequency of micronuclei will be measured from a cytological sample obtained from the oral epithelium by careful scraping of both cheeks. A fluorescence technique will be performed using acridine orange, as well as a Giemsa-Wrigth stain. The result will be reported in micronucleus frequency per 1000 cells.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nuclear anomalies frequency</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>The nuclear anomalies frequency will be measured from a cytological sample obtained from the oral epithelium by careful scraping of both cheeks. A fluorescence technique will be performed using acridine orange, as well as a Giemsa-Wrigth stain. They will be divided according to their morphology (multinucleated cells, pyknotic nucleus, karyorrhexis, caryolysis, nuclei buds, condensed chromatin) and will be reported by the number of findings per 1000 cells.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body height</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>It will be determined using the electric bioimpedance scale with electrical stadiometer. The measurement will be made with the patient standing on the marks on the bioimpedance scale, in an upright position. This determination will be reported in meters (m) with a minimum precision of 0.01 meters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>t will be determined using the electric bioimpedance scale with electrical stadiometer. The measurement will be made with the patient standing on the marks on the bioimpedance scale, in an upright position. This determination will be reported in kilograms (Kg).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body mass index</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>The calculation will be made using the results of the weight, and height. From these results will be calculated by dividing the weight obtained over the square of the height. This index will be reported in kilograms per square meter (kg / m2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin Secretion</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>The calculation will be made using the insulogenic index, using the values obtained in the oral glucose tolerance test, and determining the insulin levels in plasma at 120 minutes and at the baseline measurement, as well as the glucose levels obtained at the 120 minutes and at the baseline measurement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline Insulin Secretion</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>It will be use the Stumvoll index for the calculation of this parameter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin sensitivity</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>For the calculation of this parameter the Matsuda index will be used, from the values obtained and applying the formula.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Cholesterol</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>The determination of total cholesterol will be made from a blood sample with the patient fasting between 8 to 12 hours. Samples will be analyzed by spectrophotometry. The result will be reported in milligrams per deciliter (mg / dL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High-density lipoprotein (HDL)</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>The determination of HDL will be made from a blood sample with the patient fasting between 8 to 12 hours. Samples will be analyzed by spectrophotometry. The result will be reported in milligrams per deciliter (mg / dL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low-density lipoprotein</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>LDL will be calculated using the Friedewald formula from the results obtained of total cholesterol, HDL and triglycerides. The result will be expressed in milligrams per deciliter (mg / dl).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>The determination of triglycerides will be made from a blood sample with the patient fasting between 8 to 12 hours. Samples will be analyzed by spectrophotometry. The result will be reported in milligrams per deciliter (mg / dL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Lactate</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>The determination of serum lactate will be made from a blood sample with the patient fasting between 8 to 12 hours. Samples will be analyzed by spectrophotometry. The result will be reported in millimoles per Liter (mg / dL).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Sleep quality</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>It will be determined by the Pittsburgh Sleep Quality Index (PSQI). This will be done by interviewing the patient and each of the components is scored. The result will be expressed in points, and a total score equal to or less than 5 will be taken as reference to determine a good sleep quality.</description>
  </other_outcome>
  <other_outcome>
    <measure>Tolerability to treatment</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>The patient will be instructed to record in a follow-up diary any condition, alteration or change in the state of health that could occur during the period of the intervention. In addition to this, there is the contact section where you can communicate with the investigating doctor, or protocol director to report alterations. The report of adverse effects presented as a result of the intervention will be made.</description>
  </other_outcome>
  <other_outcome>
    <measure>Treatment attachment</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>The attachment to treatment will be determined by quantifying remaining capsules in the bottle during monthly follow-up appointments. At the end of the study, the sum of all the capsules per medicine will be made and it will be classified as an adequate attachment to those that meet ≥ 80% of the doses during the 90 days of intervention.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>PreDiabetes</condition>
  <arm_group>
    <arm_group_label>melatonin plus metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>It will be indicate metformin 850 mg tablets, once a day in the morning (before breakfast) per 90 days.
Will administrate melatonin 5 mg lengthed release capsules, once a day in the night (before bedtime) per 90 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>metformin plus placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>It will be indicate metformin 850 mg tablets, once a day in the morning (before breakfast) per 90 days.
Will administrate homologated placebo once a day in the night (before bedtime) per 90 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>melatonin plus placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>It will be indicate homologated placebo once a day in the morning (before breakfast) per 90 days.
Will administrate melatonin 5 mg lengthed release capsules, once a day in the night (before sleep) per 90 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melatonin</intervention_name>
    <description>The administration of melatonin will be indicated at night before bedtime to avoid alterations of the circadian cycle. It will be contained in bottles labeled &quot;Medication 2&quot; to maintain the masking. This intervention will be indicated in two groups (Melatonin plus metformin and Melatonin plus placebo)</description>
    <arm_group_label>melatonin plus metformin</arm_group_label>
    <arm_group_label>melatonin plus placebo</arm_group_label>
    <other_name>Cronocaps</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin</intervention_name>
    <description>For the intervention with metformin, prolonged-release tablets will be used to reduce adverse effects and improve adherence to treatment. It will be contained in bottles labeled &quot;Medication 1&quot; to maintain masking. This intervention will be indicated in two groups (Melatonin plus metformin and metformin plus placebo)</description>
    <arm_group_label>melatonin plus metformin</arm_group_label>
    <arm_group_label>metformin plus placebo</arm_group_label>
    <other_name>Ifor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The placebo may be contained in bottles labeled &quot;Medication 1&quot; or &quot;Medication 2&quot; depending on the time of administration, and the group in which it is used. Placebo will be used in two groups (Melatonin plus placebo and Metformin plus placebo)</description>
    <arm_group_label>melatonin plus placebo</arm_group_label>
    <arm_group_label>metformin plus placebo</arm_group_label>
    <other_name>Calcined magnesia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age beween 30 to 60 years old.

          -  Diagnosis of Prediabetes state according to the American Diabetes Association
             criteria.

          -  Without pharmacological treatment.

          -  Body mass index between 25 to 34.9 Kg/m2

          -  Sign informed consent

        Exclusion Criteria:

          -  Patients with pharmacological treatment.

          -  Pregnant woman

          -  Patients with autoimmune, cancer, reumatic diases history or with pharmaceutical
             treatment

          -  Workers on night or changing shifts.

          -  Subjects that have been exposed to radiation

          -  Dyslipidemia: Total cholesterol &gt;250mg/dL, Triglycerides &gt;500 mg/dL.

          -  Subjects that have travel to other place with a different time zone.

          -  Patients with diagnosis of insomnia

          -  Patients with a glomerular filtration &lt;60 ml/min using the Cockroft-Gault Formula.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lizet Yadira Rosales-Rivera, PhD Science</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto de terapeutica experimental y clínica</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lizet Y Rosales-Rivera, PhD Science</last_name>
    <phone>52 33 10585200</phone>
    <phone_ext>34212</phone_ext>
    <email>lizet.rosales@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Leo E Santacruz-Meneses, PhD Student</last_name>
    <phone>52 33 10585200</phone>
    <phone_ext>34212</phone_ext>
    <email>leosantmene90@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institute of Experimental and Clinical Therapeutics (INTEC), CUCS, University of Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44340</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lizet Yadira Rosales-Rivera, PhD Science</last_name>
      <phone>52+ (33) 1058-5200</phone>
      <phone_ext>34211</phone_ext>
      <email>lizet.rosales@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Esperanza Martínez, PhD Science</last_name>
      <phone>52+(33) 1058-5200</phone>
      <phone_ext>34211</phone_ext>
      <email>esperanzamartnezabundi@yahoo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018 Jan;41(Suppl 1):S13-S27. doi: 10.2337/dc18-S002. Review.</citation>
    <PMID>29222373</PMID>
  </reference>
  <reference>
    <citation>Brannick B, Wynn A, Dagogo-Jack S. Prediabetes as a toxic environment for the initiation of microvascular and macrovascular complications. Exp Biol Med (Maywood). 2016 Jun;241(12):1323-31. doi: 10.1177/1535370216654227. Review.</citation>
    <PMID>27302176</PMID>
  </reference>
  <reference>
    <citation>Ferrannini E, Gastaldelli A, Iozzo P. Pathophysiology of prediabetes. Med Clin North Am. 2011 Mar;95(2):327-39, vii-viii. doi: 10.1016/j.mcna.2010.11.005. Review.</citation>
    <PMID>21281836</PMID>
  </reference>
  <reference>
    <citation>Wilson ML. Prediabetes: Beyond the Borderline. Nurs Clin North Am. 2017 Dec;52(4):665-677. doi: 10.1016/j.cnur.2017.07.011. Epub 2017 Oct 5. Review.</citation>
    <PMID>29080583</PMID>
  </reference>
  <reference>
    <citation>Hostalek U, Gwilt M, Hildemann S. Therapeutic Use of Metformin in Prediabetes and Diabetes Prevention. Drugs. 2015 Jul;75(10):1071-94. doi: 10.1007/s40265-015-0416-8. Review.</citation>
    <PMID>26059289</PMID>
  </reference>
  <reference>
    <citation>Serrano R, García-Soidán FJ, Díaz-Redondo A, Artola S, Franch J, Díez J, Carrillo L, Ezkurra P, Millaruelo JM, Seguí M, Sangrós FJ, Martínez-Candela J, Muñoz P, Goday A, Regidor E; Grupo de Estudio PREDADS. [Cohort Study in Primary Health Care on the Evolution of Patients with Prediabetes (PREDAPS): basis and methodology]. Rev Esp Salud Publica. 2013 Mar-Apr;87(2):121-35. doi: 10.4321/S1135-57272013000200003. English, Spanish.</citation>
    <PMID>23775102</PMID>
  </reference>
  <reference>
    <citation>Yang H, Jin X, Kei Lam CW, Yan SK. Oxidative stress and diabetes mellitus. Clin Chem Lab Med. 2011 Nov;49(11):1773-82. doi: 10.1515/CCLM.2011.250. Epub 2011 Aug 3. Review.</citation>
    <PMID>21810068</PMID>
  </reference>
  <reference>
    <citation>Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010 Oct 29;107(9):1058-70. doi: 10.1161/CIRCRESAHA.110.223545. Review.</citation>
    <PMID>21030723</PMID>
  </reference>
  <reference>
    <citation>Tang WH, Martin KA, Hwa J. Aldose reductase, oxidative stress, and diabetic mellitus. Front Pharmacol. 2012 May 9;3:87. doi: 10.3389/fphar.2012.00087. eCollection 2012.</citation>
    <PMID>22582044</PMID>
  </reference>
  <reference>
    <citation>Rolo AP, Palmeira CM. Diabetes and mitochondrial function: role of hyperglycemia and oxidative stress. Toxicol Appl Pharmacol. 2006 Apr 15;212(2):167-78. Epub 2006 Feb 20. Review.</citation>
    <PMID>16490224</PMID>
  </reference>
  <reference>
    <citation>Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001 Dec 13;414(6865):813-20.</citation>
    <PMID>11742414</PMID>
  </reference>
  <reference>
    <citation>Torres-Bugarín O, Zavala-Cerna MG, Nava A, Flores-García A, Ramos-Ibarra ML. Potential uses, limitations, and basic procedures of micronuclei and nuclear abnormalities in buccal cells. Dis Markers. 2014;2014:956835. doi: 10.1155/2014/956835. Epub 2014 Feb 4. Review.</citation>
    <PMID>24778463</PMID>
  </reference>
  <reference>
    <citation>Jdey W, Thierry S, Popova T, Stern MH, Dutreix M. Micronuclei Frequency in Tumors Is a Predictive Biomarker for Genetic Instability and Sensitivity to the DNA Repair Inhibitor AsiDNA. Cancer Res. 2017 Aug 15;77(16):4207-4216. doi: 10.1158/0008-5472.CAN-16-2693. Epub 2017 Jun 6.</citation>
    <PMID>28588010</PMID>
  </reference>
  <reference>
    <citation>Kisurina-Evgenieva OP, Sutiagina OI, Onishchenko GE. Biogenesis of Micronuclei. Biochemistry (Mosc). 2016 May;81(5):453-64. doi: 10.1134/S0006297916050035. Review.</citation>
    <PMID>27297896</PMID>
  </reference>
  <reference>
    <citation>Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong JK, Furlong TJ, Greenfield JR, Greenup LC, Kirkpatrick CM, Ray JE, Timmins P, Williams KM. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 2011 Feb;50(2):81-98. doi: 10.2165/11534750-000000000-00000. Review.</citation>
    <PMID>21241070</PMID>
  </reference>
  <reference>
    <citation>Gong L, Goswami S, Giacomini KM, Altman RB, Klein TE. Metformin pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics. 2012 Nov;22(11):820-7. doi: 10.1097/FPC.0b013e3283559b22. Review.</citation>
    <PMID>22722338</PMID>
  </reference>
  <reference>
    <citation>Vecchio S, Giampreti A, Petrolini VM, Lonati D, Protti A, Papa P, Rognoni C, Valli A, Rocchi L, Rolandi L, Manzo L, Locatelli CA. Metformin accumulation: lactic acidosis and high plasmatic metformin levels in a retrospective case series of 66 patients on chronic therapy. Clin Toxicol (Phila). 2014 Feb;52(2):129-35. doi: 10.3109/15563650.2013.860985. Epub 2013 Nov 28.</citation>
    <PMID>24283301</PMID>
  </reference>
  <reference>
    <citation>Lalau JD. Lactic acidosis induced by metformin: incidence, management and prevention. Drug Saf. 2010 Sep 1;33(9):727-40. doi: 10.2165/11536790-000000000-00000. Review.</citation>
    <PMID>20701406</PMID>
  </reference>
  <reference>
    <citation>Dunn CJ, Peters DH. Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs. 1995 May;49(5):721-49. Review.</citation>
    <PMID>7601013</PMID>
  </reference>
  <reference>
    <citation>Lardone PJ, Alvarez-Sanchez SN, Guerrero JM, Carrillo-Vico A. Melatonin and glucose metabolism: clinical relevance. Curr Pharm Des. 2014;20(30):4841-53. Review.</citation>
    <PMID>24251676</PMID>
  </reference>
  <reference>
    <citation>Brzezinski A. Melatonin in humans. N Engl J Med. 1997 Jan 16;336(3):186-95. Review.</citation>
    <PMID>8988899</PMID>
  </reference>
  <reference>
    <citation>Al-Omary FA. Melatonin: comprehensive profile. Profiles Drug Subst Excip Relat Methodol. 2013;38:159-226. doi: 10.1016/B978-0-12-407691-4.00005-8. Review.</citation>
    <PMID>23668405</PMID>
  </reference>
  <reference>
    <citation>Singh M, Jadhav HR. Melatonin: functions and ligands. Drug Discov Today. 2014 Sep;19(9):1410-8. doi: 10.1016/j.drudis.2014.04.014. Epub 2014 Apr 30. Review.</citation>
    <PMID>24792719</PMID>
  </reference>
  <reference>
    <citation>Hussain SA, Khadim HM, Khalaf BH, Ismail SH, Hussein KI, Sahib AS. Effects of melatonin and zinc on glycemic control in type 2 diabetic patients poorly controlled with metformin. Saudi Med J. 2006 Oct;27(10):1483-8.</citation>
    <PMID>17013468</PMID>
  </reference>
  <reference>
    <citation>Gamboa ML, Canales-Gómez JS, Castro Sandoval T de J. Bioavailability of Long Acting Capsules of Melatonin in Mexican Healthy Volunteers. J Bioequiv Availab. 2010 Sep 30;02(05).</citation>
  </reference>
  <reference>
    <citation>Garfinkel D, Zorin M, Wainstein J, Matas Z, Laudon M, Zisapel N. Efficacy and safety of prolonged-release melatonin in insomnia patients with diabetes: a randomized, double-blind, crossover study. Diabetes Metab Syndr Obes. 2011;4:307-13. doi: 10.2147/DMSO.S23904. Epub 2011 Aug 2.</citation>
    <PMID>21887103</PMID>
  </reference>
  <reference>
    <citation>McMullan CJ, Schernhammer ES, Rimm EB, Hu FB, Forman JP. Melatonin secretion and the incidence of type 2 diabetes. JAMA. 2013 Apr 3;309(13):1388-96. doi: 10.1001/jama.2013.2710.</citation>
    <PMID>23549584</PMID>
  </reference>
  <reference>
    <citation>Thomas AP, Hoang J, Vongbunyong K, Nguyen A, Rakshit K, Matveyenko AV. Administration of Melatonin and Metformin Prevents Deleterious Effects of Circadian Disruption and Obesity in Male Rats. Endocrinology. 2016 Dec;157(12):4720-4731. Epub 2016 Sep 21.</citation>
    <PMID>27653034</PMID>
  </reference>
  <reference>
    <citation>Reutrakul S, Sumritsopak R, Saetung S, Chanprasertyothin S, Chailurkit LO, Anothaisintawee T. Lower nocturnal urinary 6-sulfatoxymelatonin is associated with more severe insulin resistance in patients with prediabetes. Neurobiol Sleep Circadian Rhythms. 2017 Jun 28;4:10-16. doi: 10.1016/j.nbscr.2017.06.001. eCollection 2018 Jan.</citation>
    <PMID>31236502</PMID>
  </reference>
  <reference>
    <citation>Park JH, Shim HM, Na AY, Bae KC, Bae JH, Im SS, Cho HC, Song DK. Melatonin prevents pancreatic β-cell loss due to glucotoxicity: the relationship between oxidative stress and endoplasmic reticulum stress. J Pineal Res. 2014 Mar;56(2):143-53. doi: 10.1111/jpi.12106. Epub 2013 Nov 25.</citation>
    <PMID>24168371</PMID>
  </reference>
  <reference>
    <citation>Rybka J, Kędziora-Kornatowska K, Kupczyk D, Muszalik M, Kornatowski M, Kędziora J. Antioxidant effect of immediate- versus sustained-release melatonin in type 2 diabetes mellitus and healthy controls. Drug Deliv. 2016;23(3):814-7. doi: 10.3109/10717544.2014.917343. Epub 2014 May 28.</citation>
    <PMID>24865293</PMID>
  </reference>
  <reference>
    <citation>Lo CC, Lin SH, Chang JS, Chien YW. Effects of Melatonin on Glucose Homeostasis, Antioxidant Ability, and Adipokine Secretion in ICR Mice with NA/STZ-Induced Hyperglycemia. Nutrients. 2017 Oct 29;9(11). pii: E1187. doi: 10.3390/nu9111187.</citation>
    <PMID>29109369</PMID>
  </reference>
  <reference>
    <citation>Onaran I, Guven GS, Ozdaş SB, Kanigur G, Vehid S. Metformin does not prevent DNA damage in lymphocytes despite its antioxidant properties against cumene hydroperoxide-induced oxidative stress. Mutat Res. 2006 Dec 10;611(1-2):1-8. Epub 2006 Sep 26.</citation>
    <PMID>17000131</PMID>
  </reference>
  <reference>
    <citation>Skrha J, Prázný M, Hilgertová J, Kvasnicka J, Kalousová M, Zima T. Oxidative stress and endothelium influenced by metformin in type 2 diabetes mellitus. Eur J Clin Pharmacol. 2007 Dec;63(12):1107-14. Epub 2007 Sep 15.</citation>
    <PMID>17874238</PMID>
  </reference>
  <reference>
    <citation>AIDS networking in Canada, US. CMAJ. 1995 Dec 15;153(12):1772.</citation>
    <PMID>8529190</PMID>
  </reference>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 15, 2019</study_first_submitted>
  <study_first_submitted_qc>February 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2019</study_first_posted>
  <last_update_submitted>September 24, 2019</last_update_submitted>
  <last_update_submitted_qc>September 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Guadalajara</investigator_affiliation>
    <investigator_full_name>Lizet Yadira Rosales Rivera</investigator_full_name>
    <investigator_title>Profesor investigador asociado C</investigator_title>
  </responsible_party>
  <keyword>Melatonin</keyword>
  <keyword>Metformin</keyword>
  <keyword>Pre Diabetes</keyword>
  <keyword>PreDiabetes</keyword>
  <keyword>Micronuclei</keyword>
  <keyword>Genotoxicity Markers</keyword>
  <keyword>Cytotoxicity Markers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

